"RethinkBH and Raintree are combining our strengths to deliver tools that meet the real-world needs of multidisciplinary therapy practices," said Rethink CEO Ben Semmes. "We want to make life easier ...

Extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) have become a critical global public health challenge due to their high resistance to β-lactam antibiotics and association with severe ...

The report highlights market opportunities by offering strategic insights into global rhabdomyosarcoma clinical trials. Key opportunities include identifying optimal locations for trials, ...

Key market opportunities include strategic investment in Idiopathic Pulmonary Fibrosis trials, optimizing trial locations to reduce costs, and leveraging top-level data for strategic planning.

Company reports Q3 2025 AUCATZYL® net product revenue of $21.1 million and deferred revenue of $7.6 million; 60 authorized treatment centers ...

Expanded data for VCN-01 (zabilugene almadenorepvec) in metastatic pancreatic ductal adenocarcinoma (PDAC) from the VIRAGE Phase 2b trial ...

Xia, R. , Blimberg, C. , Sotelo, F. and Vandernaalt, Z. (2025) Effects of Aerobic Exercise on Physical, Mental, and Cognitive ...

Grid My Business introduces a new suite of live shareable reports, smarter review and ranking analysis, and improved data tools that simplify how businesses and agencies handle local SEO. New York, ...

Introduction Burnout and reduced well-being are highly prevalent among Japanese medical students during clinical training. Scalable, evidence-based interventions are urgently needed. This protocol ...

Inspire Medical Systems, Inc. ( INSP) UBS Global Healthcare Conference 2025 November 10, 2025 11:45 AM EST ...

Press Advantage, a leading press release distribution company, today highlighted a growing trend among solo entrepreneurs and small business owners who are abandoning traditional PR agency retainers ...

Acurx Pharmaceuticals, Inc. ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today ...